A peptide-antisense oligonucleotide (peptide-AON) conjugate comprising a cationic cell penetrating peptide covalently conjugated to at least two antisense oligonucleotides, wherein the peptide-AON conjugate is selected from the group consisting of: (i) Ac- 4 XFKE-( 2 -AON)G-; (ii) Ac-(RXRRBR) 2 XFKE G; (iii) Ac-(RXRRBR) 2 XFD(D-Glu) E G; (iv) Ac-E (RXRRBR) 2 XFKG; (v) Ac-E (RXRRBR) 2 XFKE G; (vi) Ac-E (RXRRBR) 2 XFK(D-Glu) E G; (vii) Ac-(D-Glu) E (RXRRBR) 2 XFKG-amide; (viii) Ac-(D-Glu) E (RXRRBR) 2 XFKG; (ix) Ac-(D-Glu) E (RXRRBR) 2 XFKE G; (x) Ac-(D-Glu) E (RXRRBR) 2 XFK(D-Glu) E G, (xi) Ac- 4 XE-( 2 -AON)G-; and (xii) Ac-(RXRRBR) 2 XE G, wherein Ac is acetyl, R is D-arginine, X is 6-aminohexanoic acid, B is β-alanine, E is glutamic acid, D-Glu is D-glutamic acid, and G is glycine, wherein each AON comprises 15 to 30 subunits of a phosphorodiamidate morpholino oligomer, peptide nucleic acid, phosphoramidate, methylene methylimino, 2-O-methyl (2-OMe), or 2-methyl ethyl (2-MOE), wherein each subunit comprises a naturally occurring purine or pyrimidine nucleotide base selected from C, G, A, or T; wherein each AON comprises: (i) a nucleotide base sequence that is complementary to at least 75% of the bases of a target pre-mRNA, mRNA, microRNA, or long non-coding RNA of a gene; (ii) from 0 to 3 repeating subunits where said naturally occurring purine or pyrimidine nucleotide base is G; (iii) less than 60% of said subunits where naturally occurring purine or pyrimidine nucleotide base is C or G; and (iv) a non-self-complimentary sequence, and wherein the peptide-AON conjugate comprises at least one cleavable linker comprising a sequence that contains a cleavage motif for a hydrolytic enzyme. wherein the peptide-AON conjugate is selected from the group consisting of: (i) Ac- 4 XFKE-( 2 -AON)G-; (ii) Ac-(RXRRBR) 2 XFKE G; (iii) Ac-(RXRRBR) 2 XFD(D-Glu) E G; (iv) Ac-E (RXRRBR) 2 XFKG; (v) Ac-E (RXRRBR) 2 XFKE G; (vi) Ac-E (RXRRBR) 2 XFK(D-Glu) E G; (vii) Ac-(D-Glu) E (RXRRBR) 2 XFKG-amide; (viii) Ac-(D-Glu) E (RXRRBR) 2 XFKG; (ix) Ac-(D-Glu) E (RXRRBR) 2 XFKE G; (x) Ac-(D-Glu) E (RXRRBR) 2 XFK(D-Glu) E G, (xi) Ac- 4 XE-( 2 -AON)G-; and (xii) Ac-(RXRRBR) 2 XE G, wherein Ac is acetyl, R is D-arginine, X is 6-aminohexanoic acid, B is β-alanine, E is glutamic acid, D-Glu is D-glutamic acid, and G is glycine, (i) Ac- 4 XFKE-( 2 -AON)G-; (ii) Ac-(RXRRBR) 2 XFKE G; (iii) Ac-(RXRRBR) 2 XFD(D-Glu) E G; (iv) Ac-E (RXRRBR) 2 XFKG; (v) Ac-E (RXRRBR) 2 XFKE G; (vi) Ac-E (RXRRBR) 2 XFK(D-Glu) E G; (vii) Ac-(D-Glu) E (RXRRBR) 2 XFKG-amide; (viii) Ac-(D-Glu) E (RXRRBR) 2 XFKG; (ix) Ac-(D-Glu) E (RXRRBR) 2 XFKE G; (x) Ac-(D-Glu) E (RXRRBR) 2 XFK(D-Glu) E G, (xi) Ac- 4 XE-( 2 -AON)G-; and (xii) Ac-(RXRRBR) 2 XE G, wherein each AON comprises 15 to 30 subunits of a phosphorodiamidate morpholino oligomer, peptide nucleic acid, phosphoramidate, methylene methylimino, 2-O-methyl (2-OMe), or 2-methyl ethyl (2-MOE), wherein each subunit comprises a naturally occurring purine or pyrimidine nucleotide base selected from C, G, A, or T; wherein each AON comprises: (i) a nucleotide base sequence that is complementary to at least 75% of the bases of a target pre-mRNA, mRNA, microRNA, or long non-coding RNA of a gene; (ii) from 0 to 3 repeating subunits where said naturally occurring purine or pyrimidine nucleotide base is G; (iii) less than 60% of said subunits where naturally occurring purine or pyrimidine nucleotide base is C or G; and (iv) a non-self-complimentary sequence, and (i) a nucleotide base sequence that is complementary to at least 75% of the bases of a target pre-mRNA, mRNA, microRNA, or long non-coding RNA of a gene; (ii) from 0 to 3 repeating subunits where said naturally occurring purine or pyrimidine nucleotide base is G; (iii) less than 60% of said subunits where naturally occurring purine or pyrimidine nucleotide base is C or G; and (iv) a non-self-complimentary sequence, and wherein the peptide-AON conjugate comprises at least one cleavable linker comprising a sequence that contains a cleavage motif for a hydrolytic enzyme.